Management of Severe Neutropenia and Leukopenia

Diagnostic and Management Approach

Blood cultures and other appropriate cultures should be taken before starting antibiotics in patients with febrile neutropenia, as recommended by the National Comprehensive Cancer Network 1
Avoid invasive procedures such as central venous catheterization, lumbar puncture, and bronchoscopy due to high risk of hemorrhagic complications in patients with severe neutropenia, as suggested by research published in Blood 2, 3

The American Society of Clinical Oncology recommends starting ATRA (all-trans retinoic acid) immediately upon suspicion of Acute Promyelocytic Leukemia (APL) diagnosis, and maintaining platelet counts above 30-50 × 10^9/L and fibrinogen above 100-150 mg/dL 3
Administer lymphodepleting conditioning regardless of WBC count in patients preparing for CAR-T cell therapy, as recommended by the European Society for Medical Oncology 4
Hydroxyurea (50-60 mg/kg/day) can be used to reduce white blood cell counts to less than 10-20 × 10^9/L in patients with Acute Myeloid Leukemia (AML) with Hyperleukocytosis, as suggested by research published in Blood 5, 6

Antimicrobial prophylaxis may be considered in prolonged neutropenia based on institutional protocols, and antifungal prophylaxis with posaconazole has been shown to significantly decrease fungal infections compared to fluconazole in high-risk patients, as recommended by the National Comprehensive Cancer Network 1
Avoid azole antifungals during anthracycline chemotherapy due to drug interactions that can increase toxicity, as warned by the National Comprehensive Cancer Network 1

Avoid leukapheresis in APL patients with hyperleukocytosis due to risk of precipitating fatal hemorrhage, as warned by research published in Blood and the National Comprehensive Cancer Network 1, 3

The primary treatment for low white blood cell count (leukopenia) should be directed at the underlying cause, with granulocyte colony-stimulating factors (G-CSFs) reserved for severe neutropenia with high risk of infection or as prophylaxis during chemotherapy, as recommended by the American Society of Clinical Oncology 7
G-CSFs should not be routinely used as adjunctive treatment with antibiotic therapy for all patients with fever and neutropenia, but should be considered in high-risk patients with expected prolonged and profound neutropenia, age greater than 65 years, uncontrolled primary disease, pneumonia, hypotension, or multiorgan dysfunction, as recommended by the American Society of Clinical Oncology 7
For patients with leukemia and elevated WBC counts, prompt institution of definitive therapy is essential after measures to rapidly reduce WBC count, according to the National Comprehensive Cancer Network 8, 9
In patients with acute leukemia, treatment should be directed at the underlying malignancy according to specific protocols, as recommended by the National Comprehensive Cancer Network 8, 9, 10